Guardant Health, Inc. Cash and Equivalents

Quick Answer

Guardant Health, Inc. reported Cash and Equivalents of $378.20 million for fiscal year 2025.

Guardant Health, Inc. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $378.20M -28.0%
2024 $525.54M -53.6%
2023 $1.13B +700.3%
2022 $141.65M -71.2%
2021 $492.20M -40.9%
2020 $832.98M +481.6%
2019 $143.23M +1.9%
2018 $140.54M +94.4%
2017 $72.28M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2025 $580.01M -0.9% -7.8%
June 30, 2025 $629.14M -32.6% -9.9%
March 31, 2025 $698.57M -32.1% +32.9%
December 31, 2024 $525.54M -10.2%
September 30, 2024 $585.02M +27.9% -37.3%
June 30, 2024 $933.69M +244.4% -9.3%
March 31, 2024 $1.03B +360.1% +125.0%
September 30, 2023 $457.34M +188.9% +68.7%
  • Guardant Health, Inc. showed a decrease of -28.0% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2017–2025 period, Guardant Health, Inc.’s cash and equivalents has grown by 423.2% (from $72.28 million to $378.20 million).
  • The most recent figure is from Guardant Health, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment